Abstract
New Orleans, La. From Obatala Sciences, Inc. Received for publication July 6, 2021; accepted September 30, 2021. Disclosure:The author is a co-founder, co-owner, and chief scientific officer of Obatala Sciences, Inc., and LaCell, LLC, for-profit biotechnology companies focusing on the clinical translation of adipose-derived cells and extracellular matrix products for regenerative medicine. He is also a co-owner and co-founder of Talaria Antibodies, Inc., and the inventor on patents related to adipose and stromal/stem cell research applications. Jeffrey M. Gimble, M.D., Ph.D., Obatala Sciences, Inc., 2000 Lakeshore Drive, Suite 4020, New Orleans, La. 70122 [email protected]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
